The Institute for Clinical and Economic Review (ICER) on Dec. 21 released a Final Evidence Report and Report-at-a-Glance on vesicular monoamine transporter 2 (VMAT2) inhibitors for management of tardive dyskinesia (TD).
TD is a repetitive, involuntary movement disorder caused by prolonged use of certain medications, most commonly antipsychotic drugs used to treat schizophrenia and affective disorders. The report reviews evidence on the comparative clinical effectiveness and value of valbenazine (Ingrezza, Neurocrine Biosciences, Inc.), deutetrabenazine (Austedo, Teva), and tetrabenazine (Xenazine, Lundbeck and multiple generics).
Both valbenazine and deutetrabenazine were approved earlier this year for treatment of TD; tetrabenazine was approved in 2008 for use in Huntington’s disease, a rare condition, and has been used to treat TD despite lacking a formal indication for the disorder. Although TD is far more prevalent than Huntington’s disease, the announced list prices of both valbenazine and deutetrabenazine are similar to tetrabenazine’s rare-disease price.